Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Drug Safety|April 27, 2013
Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)Rashmi R Shah, Joel Morganroth, Devron R ShahSupportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 27, 2015
Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteersJoel Morganroth, Kristen K Flaharty, Simona Parisi, et al.Drug Safety|February 19, 2013
Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?Norman Stockbridge, Joel Morganroth, Rashmi R Shah, et al.Regional Anesthesia and Pain Medicine|January 24, 2012
Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profileSergio D Bergese, Erol Onel, Michael Morren, et al.Journal of Electrocardiology|May 11, 2004
Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug developmentIhor Gussak, Jeffrey Litwin, Robert Kleiman, et al.Journal of Clinical Pharmacology|May 23, 2002
The pharmacokinetics and safety of single escalating oral doses of eletriptanAjit K Shah, Stephen C Harris, Catherine Greenhalgh, et al.Journal of Clinical Pharmacology|June 17, 2004
Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjectsSteven Barriere, Fredric Genter, Elizabeth Spencer, et al.Chest|November 24, 2005
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumoniaJoel Morganroth, John P Dimarco, Antonio Anzueto, et al.Postgraduate Medicine|December 9, 2016
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trialsStephen C Harris, Joel Morganroth, Steven R Ripa, et al.Expert Opinion on Pharmacotherapy|December 11, 2012
Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG studyJoel Morganroth, Daniel D Gretler, Stanley J Hollenbach, et al.Pageof 4